Arthur DeCillis

Prior to forming his own consulting practice, Arthur “Art” DeCillis, MD was the Chief Medical Officer for Eleven Biotherapeutics (now known as Sesen Bio Inc.), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies. Previously, Art was the Vice President of Clinical Research and then Vice President of Medical Affairs at Exelixis, Inc., an oncology-focused biotechnology company. He also previously served as Executive Director of Oncology Development at Novartis and Group Director of Bristol-Myers Squibb. Art has been involved in the development of several commercialized oncology drugs including SPRYCEL® (dasatinib), AFINITOR® (everolimus), FARYDAK® (panobinostat), and CABOMETYX® (cabozantinib).

Art holds an M.D. from University of Rochester and completed an internal medicine residency at Medical College of Virginia followed by a fellowship at University of Pittsburgh.